Mackenzie Financial’s Enanta Pharmaceuticals ENTA Stock Holding History

Mackenzie Financial’s Portfolio ENTA Stock Details ENTA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$982K	Buy	+67,367	New	+$905K	﹤0.01%	1195
2019 Q3	–	Sell	-37,753	Closed	-$3.19M	–	1034
2019 Q2	$3.19M	Buy	37,753 +34,843	+1,197%	+$3.13M	0.01%	538
2019 Q1	$278K	Sell	2,910 -90	-3%	-$8.07K	﹤0.01%	1122
2018 Q4	$212K	Sell	3,000 -26,275	-90%	-$2.01M	﹤0.01%	1086
2018 Q3	$2.5M	Sell	29,275 -6,005	-17%	-$602K	0.01%	609
2018 Q2	$4.09M	Buy	35,280 +17,000	+93%	+$1.7M	0.01%	491
2018 Q1	$1.48M	Buy	+18,280	New	+$1.41M	﹤0.01%	598

Other funds holding ENTA

Jupiter Topco New York $245B AUM

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

KAM

Krensavage Asset Management New York $263M AUM 66.99% 1-Year Est. Return

FCM

Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return

DTC

Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return

ACM

ADAR1 Capital Management Austin, Texas $2.19B AUM 374.99% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

SSC

Spruce Street Capital New York $510M AUM

Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Mackenzie Financial's ENTA Position: Q2 2026 in Review

Mackenzie Financial opened a new position in Enanta Pharmaceuticals (ENTA) in Q2 2026: 67,367 shares worth $982K. The stake represents ﹤0.01% of the portfolio and ranks #1195 among its holdings. This is a return to the name: Mackenzie Financial previously reported a position in ENTA as recently as Q2 2019.

Mackenzie Financial first reported a position in ENTA in Q1 2018 and has held it in 7 quarters since. The position peaked at $4.09M in Q2 2018. 123 funds tracked by Wall St. Rank hold ENTA as of Q2 2026.

Mackenzie Financial held 67,367 shares of Enanta Pharmaceuticals worth $982K as of Q2 2026.
Enanta Pharmaceuticals was a new Mackenzie Financial position in Q2 2026.
Enanta Pharmaceuticals made up ﹤0.01% of Mackenzie Financial's portfolio in Q2 2026, its #1195 holding.
Mackenzie Financial first reported a position in Enanta Pharmaceuticals in Q1 2018 and has held it in 7 quarters since.
Mackenzie Financial's Enanta Pharmaceuticals position peaked at $4.09M in Q2 2018.
123 funds tracked by Wall St. Rank held Enanta Pharmaceuticals as of Q2 2026.

Based on Mackenzie Financial's 13F filing for Q2 2026, filed 13 Aug 2026.